$NTHI

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI): Submission of Matters to a Vote of Security Holders

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. NeOnc Technologies Holdings, Inc. (the “Company”) held its 2026 annual meeting of stockholders on August 14, 2026 (the “Annual Meeting”) via live webcast. For more information about the proposals set forth below, ple

Original reporting
Published Aug 20, 2026, 1:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 1:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$NTHI
Neutral
high confidence
Mentioned
$NTHI
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NTHINeutralLow
01

Why it matters

The disclosed votes confirm the election of two Class I directors, approval of an amended equity incentive plan, and ratification of the auditor. These are standard governance items with no immediate financial impact.

02

Market read

Low relevance for traders; the filing provides routine corporate governance information without material financial implications.

03

What to watch

None; the meeting outcomes do not affect valuation.

Relevance 6/10Novelty 2/10Timing: filed Aug 20 2026

Background

The company filed a current report (Form 8‑K) to disclose the outcomes of its annual meeting, as required by SEC regulations.

Company-level read

Ticker impact

$NTHINeutralHigh confidence
Context

SEC Form 8‑K reports the results of the August 14, 2026 annual shareholder meeting, including election of directors and approval of the equity incentive plan.

Expected impact

minimal impact; stock likely to trade flat

Evidence & confidence

The filing confirms standard governance actions; no new financing, acquisition, or operational shift is disclosed.

Market effects

none

none

none

Counterpoint

No contrarian angle; the filing is purely procedural.

Key entities

  • NeonC Technologies Holdings, Inc.

    Issuer of the Form 8‑K and subject of the proxy vote.

Related articles

$NTHIMed

Stonegate, Inc.: Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

Stonegate Capital Partners updated coverage of NeOnc Technologies Holdings (NASDAQ: NTHI), citing 2Q26 progress for NEO100 and NEO212. NEO100 Phase 2a reported PFS at 6 months of 48.9% vs a 20% benchmark (p=0.0047), median OS 26.09 months, and no major toxicities. NeOnc plans a Type B FDA meeting; R&D rose to $2.6M from $0.7M year over year.

$NTHIMed

WallStreet-PR: NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Holdings (NASDAQ: NTHI) reported Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. It said six-month progression-free survival was 48.9% versus a 20% historical benchmark, with p=0.0047. Median overall survival was about 26 months, with no major toxicities. NeOnc plans an FDA meeting on next trial steps.

$NTHIMedAI 8/10

NeOnc Technologies Reports Positive Topline Data Of NEO100 Phase 2a Study, Stock Up In Pre-Market

NeOnc Technologies Holdings (NTHI) reported positive topline Phase 2a results for intranasal NEO100 (NEO100-01) in IDH1-mutant Grade IV glioma or Grade III astrocytoma. In 24 patients at 1,152 mg/day, six-month progression-free survival was 48.9% vs 20% expected. Median overall survival was 26.09 months. Company plans an FDA Type B meeting and will present full safety data.

$NTHIHighAI 9/10

Why is Neonc Technologies stock surging today?

Investing.com reports Neonc Technologies Holdings Inc (NTHI) shares rose 11.3% pre-open after its Phase 2a NEO100-01 intranasal NEO100 study in Grade III/IV IDH1-mutant glioma met the primary endpoint. Six-month progression-free survival was 48.9% vs a 20% benchmark (p=0.0047) in 24 patients. Company discussed efficacy, safety, and next regulatory steps.

$NTHIMedAI 8/10

NeOnc Technologies stock jumps on positive glioma trial data

NeOnc Technologies Holdings (NASDAQ:NTHI) shares rose 11.7% after positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The study met its primary endpoint with 6-month progression-free survival of 48.9% vs a 20% benchmark (p=0.0047). Median overall survival was 26.09 months; 86.7% were alive at six months. The company plans an FDA Type B meeting.